Background: Asthma exacerbations in young children are commonly triggered by respiratory infections, with viral and bacterial pathogens playing distinct roles in symptom severity. Understanding the association between infection type and exacerbation severity, as well as the effectiveness of corticosteroid treatment, is crucial for optimizing asthma management in pediatric patients. Methods: This cross-sectional study was conducted at Hayatabad Medical Complex from January 2022 to January 2023, involving 120 children aged 1-5 years with asthma who presented with wheezing exacerbations. Respiratory samples were collected to identify viral and bacterial pathogens. Exacerbation severity was classified as mild, moderate, or severe, and children with moderate to severe symptoms received corticosteroid treatment. Outcomes included symptom resolution, time to relief, and recurrence within one month. Results: Viral infections were linked to milder exacerbations, faster symptom relief, and a higher corticosteroid treatment response, with an 88% symptom resolution rate and an average relief time of 28 hours. In contrast, bacterial and mixed infections were associated with more severe exacerbations, slower response times, and higher recurrence rates (22% and 30%, respectively). Corticosteroids were less effective in these cases, highlighting variability in treatment outcomes based on infection type. Conclusion: This study emphasizes the importance of distinguishing between viral and bacterial infections in asthma exacerbations to guide targeted treatments. While corticosteroids proved effective for viral-induced exacerbations, alternative or adjunctive therapies may be needed for bacterial infections to improve outcomes. Tailoring asthma management based on infection type may enhance symptom control and reduce recurrence in young children with asthma.